Vanguard Group Inc. Increases Holdings in Tandem Diabetes Care, Inc. $TNDM

Vanguard Group Inc. lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 3.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,341,356 shares of the medical device company’s stock after purchasing an additional 278,042 shares during the quarter. Vanguard Group Inc. owned 0.11% of Tandem Diabetes Care worth $161,363,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. ArrowMark Colorado Holdings LLC grew its position in Tandem Diabetes Care by 36.7% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 3,691,198 shares of the medical device company’s stock worth $44,811,000 after acquiring an additional 991,649 shares during the last quarter. Freestone Grove Partners LP purchased a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $22,706,000. Jacobs Levy Equity Management Inc. increased its stake in shares of Tandem Diabetes Care by 3.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,481,953 shares of the medical device company’s stock valued at $17,991,000 after buying an additional 50,646 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Tandem Diabetes Care during the fourth quarter valued at approximately $26,988,000. Finally, Baillie Gifford & Co. boosted its position in shares of Tandem Diabetes Care by 2.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,145,516 shares of the medical device company’s stock valued at $25,178,000 after purchasing an additional 24,921 shares in the last quarter.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock opened at $15.48 on Monday. The firm has a market cap of $1.06 billion, a PE ratio of -11.06 and a beta of 1.64. Tandem Diabetes Care, Inc. has a 12 month low of $9.98 and a 12 month high of $29.65. The stock has a 50 day moving average of $21.32 and a 200 day moving average of $20.33. The company has a current ratio of 3.58, a quick ratio of 3.07 and a debt-to-equity ratio of 4.54.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The business had revenue of $247.22 million during the quarter, compared to analyst estimates of $240.41 million. During the same period last year, the company earned ($0.66) EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, research analysts expect that Tandem Diabetes Care, Inc. will post -0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TNDM has been the topic of several research reports. Zacks Research upgraded Tandem Diabetes Care from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. Mizuho set a $24.00 price target on Tandem Diabetes Care in a research report on Friday. TD Cowen reiterated a “buy” rating and issued a $28.00 price target (up from $25.00) on shares of Tandem Diabetes Care in a research note on Monday, April 20th. Truist Financial raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and lifted their price target for the company from $27.00 to $35.00 in a research report on Thursday, March 19th. Finally, Rothschild & Co Redburn set a $45.00 price target on shares of Tandem Diabetes Care in a research report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tandem Diabetes Care has an average rating of “Moderate Buy” and a consensus price target of $30.16.

More Tandem Diabetes Care News

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q1 revenue came in at $247.2 million, above consensus, while adjusted EPS of -$0.30 beat the expected -$0.46, signaling better-than-expected execution. Tandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9%
• Positive Sentiment: Management highlighted record first-quarter pump shipments, sales, and gross margin, along with margin expansion and pipeline progress, which supports the view that the business model is improving. Tandem Diabetes Care Announces First Quarter 2026 Financial Results
• Positive Sentiment: TD Cowen reaffirmed a Buy rating and kept its $28 price target, reinforcing bullish sentiment from analysts after the earnings release. Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained
• Neutral Sentiment: The company also reaffirmed full-year 2026 guidance, which suggests management is not seeing a major near-term change to its outlook.
• Negative Sentiment: Despite the beat, Tandem still posted a quarterly loss and remained unprofitable, so investors may stay focused on whether revenue growth and margin gains can translate into sustained earnings improvement.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.